SCHEMBL10004570

SCHEMBL10004570

CCOC(=O)c1c(OC(C)C)c2c(=O)n(-c3ccccc3)c(C)nc2n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HKDC1 Q2TB90 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 4/20 0.47
▸ GAA P10253 1/20 0.47
▸ POLB P06746 2/20 0.44
▸ ATM Q13315 1/20 0.42
▸ CCKBR P32239 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ DRD5 P21918 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004729 0.88 HKDC1 (0.53) HKDC1ALDH1A1MAPTPOLBDRD1
SCHEMBL10003938 0.85 ALDH1A1 (0.57) HKDC1ALOX15ALDH1A1MAPTGAA
SCHEMBL10003785 0.83 ALDH1A1 (0.39) ALDH1A1MAPTGAAPOLBATM
SCHEMBL10004187 0.80 MAPT (0.47) ALOX15ALDH1A1MAPTGAAPOLB
SCHEMBL10003748 0.78 KMT2A (0.43) ALDH1A1MAPTGAAPOLBCCKBR
SCHEMBL10004047 0.77 POLB (0.45) ALOX15ALDH1A1MAPTGAAPOLB
SCHEMBL10004630 0.76 SMO (0.46) HKDC1ALDH1A1MAPTGAAPOLB
SCHEMBL10004021 0.75 MAPT (0.37) ALOX15MAPTHPGDHSD17B10KMT2A
SCHEMBL10003360 0.74 CYP1A2 (0.47) ALOX15ALDH1A1MAPTGAAATM
SCHEMBL10004958 0.72 HPGD (0.39) ALDH1A1MAPTGAAPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-8614208-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-24 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH HKDC1 2807/4885ALOX15 2403/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback